378 related articles for article (PubMed ID: 28576879)
21. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.
Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K
J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639
[TBL] [Abstract][Full Text] [Related]
22. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.
Kong G; Wunderlich M; Yang D; Ranheim EA; Young KH; Wang J; Chang YI; Du J; Liu Y; Tey SR; Zhang X; Juckett M; Mattison R; Damnernsawad A; Zhang J; Mulloy JC; Zhang J
J Clin Invest; 2014 Jun; 124(6):2762-73. PubMed ID: 24812670
[TBL] [Abstract][Full Text] [Related]
23. Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells.
Lewis ID; McDiarmid LA; Samels LM; To LB; Hughes TP
Blood; 1998 Jan; 91(2):630-40. PubMed ID: 9427719
[TBL] [Abstract][Full Text] [Related]
24. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.
Hunter AM; Newman H; Dezern AE; Steensma DP; Niyongere S; Roboz GJ; Mo Q; Chan O; Gerds A; Sallman DA; Dominguez-Viqueira W; Letson C; Balasis ME; Ball M; Kruer T; Zhang H; Lancet JE; List AF; Sekeres MA; Komrokji RS; Padron E
Clin Cancer Res; 2021 Nov; 27(22):6095-6105. PubMed ID: 34253584
[TBL] [Abstract][Full Text] [Related]
25. Myelodysplastic/myeloproliferative neoplasms.
Hyjek E; Vardiman JW
Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
[TBL] [Abstract][Full Text] [Related]
26. [Juvenile myelomonocytic leukemia: A three-case series].
Ghariani I; Jmili-Braham N; Regaieg H; Achour B; Ben Youssef Y; Sendi H; Bakir L; Kortas M
Arch Pediatr; 2016 Dec; 23(12):1264-1269. PubMed ID: 27789175
[TBL] [Abstract][Full Text] [Related]
27. Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.
Zhang J; Ranheim EA; Du J; Liu Y; Wang J; Kong G; Zhang J
J Biol Chem; 2015 Jul; 290(31):19093-103. PubMed ID: 26082490
[TBL] [Abstract][Full Text] [Related]
28. Molecular genetics of MDS/MPN overlap syndromes.
Hunter AM; Padron E
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101195. PubMed ID: 33038984
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of granulocyte-macrophage colony formation in chronic myelomonocytic leukemia: a comparative study with other myelodysplastic and myeloproliferative disorders.
Yuo A; Miyazono K; Urabe A; Takaku F
Jpn J Cancer Res; 1990 Aug; 81(8):820-6. PubMed ID: 2118895
[TBL] [Abstract][Full Text] [Related]
30. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase.
Wang JC; Lapidot T; Cashman JD; Doedens M; Addy L; Sutherland DR; Nayar R; Laraya P; Minden M; Keating A; Eaves AC; Eaves CJ; Dick JE
Blood; 1998 Apr; 91(7):2406-14. PubMed ID: 9516140
[TBL] [Abstract][Full Text] [Related]
31. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.
Padron E; Painter JS; Kunigal S; Mailloux AW; McGraw K; McDaniel JM; Kim E; Bebbington C; Baer M; Yarranton G; Lancet J; Komrokji RS; Abdel-Wahab O; List AF; Epling-Burnette PK
Blood; 2013 Jun; 121(25):5068-77. PubMed ID: 23632888
[TBL] [Abstract][Full Text] [Related]
32.
Linder K; Iragavarapu C; Liu D
Biomark Res; 2017; 5():33. PubMed ID: 29225884
[TBL] [Abstract][Full Text] [Related]
33. Juvenile myelomonocytic leukemia.
Proytcheva M
Semin Diagn Pathol; 2011 Nov; 28(4):298-303. PubMed ID: 22195407
[TBL] [Abstract][Full Text] [Related]
34. Juvenile myelomonocytic leukaemia: a case series.
Azma RZ; Zarina AL; Hamidah A; Jamal R; Sharifah NA; Ainoon O; Hamidah NH
Malays J Pathol; 2009 Dec; 31(2):121-8. PubMed ID: 20514855
[TBL] [Abstract][Full Text] [Related]
35. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Clara JA; Sallman DA; Padron E
Cancer Biol Med; 2016 Sep; 13(3):360-372. PubMed ID: 27807503
[TBL] [Abstract][Full Text] [Related]
36. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
Lasho T; Patnaik MM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
[TBL] [Abstract][Full Text] [Related]
37. Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.
Gandre-Babbe S; Paluru P; Aribeana C; Chou ST; Bresolin S; Lu L; Sullivan SK; Tasian SK; Weng J; Favre H; Choi JK; French DL; Loh ML; Weiss MJ
Blood; 2013 Jun; 121(24):4925-9. PubMed ID: 23620576
[TBL] [Abstract][Full Text] [Related]
38. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
Elife; 2022 May; 11():. PubMed ID: 35535491
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
Hosseini MM; Kurtz SE; Abdelhamed S; Mahmood S; Davare MA; Kaempf A; Elferich J; McDermott JE; Liu T; Payne SH; Shinde U; Rodland KD; Mori M; Druker BJ; Singer JW; Agarwal A
Leukemia; 2018 Nov; 32(11):2374-2387. PubMed ID: 29743719
[TBL] [Abstract][Full Text] [Related]
40. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
Kuendgen A; Kasprzak A; Germing U
Front Oncol; 2021; 11():778741. PubMed ID: 34869027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
